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Summary.-BALB/c mice born to and nursed byfemales immunized against MSV-M
showed a reduced tumour incidence and a high tumour regression rate following
MSV-M injection at 7-14 days of age. Females immunized long before mating could
also confer protection to their offspring whereas females immunized after parturition
could not. A reduced number of tumours was observed in 3 out of 14 MSV-M
injected litters whose mothers had beenpreviouslyexposed to the virus while nursing
infected offspring. Sera from suckling mice born to and nursed by immunized
mothers contained MSV-M neutralizing antibody as shown by an in vitro focus
reduction assay. Cell-free extracts from mice which developed leukaemia after
MSV-M inoculation were tested for oncogenic activity in 1-week old mice. Out of
6 extracts, 4 induced typical MSV-M tumours and 2 caused leukaemias.
BIOLOGICAL and immunological studies
of Moloney murine sarcoma virus (MSV-
M)-induced tumours in mice indicate that
neoplastic cells release infectious virus and
possess specific surface antigens capable of
inducing an immune reaction in the com-
petent host (Fefer, McCoy and Glynn,
1967a). A high incidence of spontaneous
tumour regression does in fact occur in
adult mice injected with MSV-M (Fefer,
McCoy and Glynn, 1967b). In MSV-M
injected neonates or immunosuppressed
adults, most of the ensuing tumours grow
progressively and ultimately cause the
death of the host (Fefer et al., 1967b;
Shachat, Fefer and Moloney, 1968; Law,
Ting and Allison, 1968; Hook, Chirigos
and Chan, 1969). Both cell mediated and
humoral immunity seem to be responsible
for tumour regression although their
respective roles are,still not clearly under-
stood.
MSV-M is readily neutralized in vitro
by incubation with sera from MSV-M
immunized mice (Fefer et al., 1968). In
addition, MSV-M induced primary and
transplanted tumours are inhibited by
injections of immune sera (Bubenik,
Turano and Fadda, 1969; Pearson, Red-
mon and Bass, 1973). In the present
study, the possibility of preventing MSV-
M tumourigenesis in mice by maternal
antibody transfer has been studied. Data
on the recovery of MSV-M activity from
MSV-M injected mice which subsequently
developed leukaemia are also reported.
MATERIALS AND METHODS
Animals.-BALB/c mice from our colony
were employed throughout this study.
Virus preparation.-The Moloney isolate
ofMSV was originally received as lyophilized
material (SVRP No. 104A) through the
courtesy ofDr J. B. Moloney. The virus has
since been maintained by serial in vivo
passage in 1-2 week old BALB/c mice.
Tumour cell-free extracts, prepared by
homogenization and centrifugation, were
diluted weight/volume with Hank's balanced
salt solution and the final concentration
ranged from 0 1 to 0 001 g equivalents (gEq).
Seven to 14-day old mice, born to normal or
immunized females (see below), were injected
intramuscularly (i.m.) inthethigh regionwith
0 05 ml of MSV-M tumour extract in graded
doses. They were then left with their
mothers and observed on alternate days forPREVENTION OF MURINE SARCOMA VIRUS ONCOGENESIS
tumour development and regression. After
weaning, survivors were separated according
to sex.
Immunization procedure.-Three- to 4-
month old normal females were immunized
soon after mating by intraperitoneal (i.p.)
injection with 0-20 ml of 0-01 gEq tumour
extract. A second i.m. injection of0-20 ml of
0 1 gEq was given 7-10 days later and a third
and final injection of0-20 ml of0.01 gEq was
given i.p. 7-10 days after parturition (which
was the same time at which the offspring were
inoculated). Another group of female mice
were immunizedpostpartum and received the
same doses of tumour extract as above on
Days 1, 6 and 12 following parturition. A
third group consisted of females which had
previously nursed an MSV-M inoculated litter
and were therefore considered virus " ex-
posed ". A last group of females received
3 immunizing injections 6-29 weeks before
mating. This group included some mothers
from the first group who were subsequently
re-mated. None of the variously treated
mothers developed MSV-M tumours as a
result of the immunization.
Neutralization test.-The in vitro test for
virus neutralizing antibodies was performed
by a focus reduction method (Hartley and
Rowe, 1966). Briefly, blood was collected
from the retro-orbital sinus of immunized
mothers and their litters 10-16 days after
parturition, at a time corresponding approxi-
mately to MSV-M inoculation in suckling
mice. The sera were pooled, inactivated at
56°C for 30 min, and incubated at an appro-
priatedilutionfor 60 min atroomtemperature
with 40 FFU (focus forming units) ofMSV-M.
Sera from 2 normal mothers and their respec-
tive litters were used as controls. The mix-
ture of serum and MSV-M was then assayed
forfocus formation on DEAE-dextrantreated
NIH/3T3 mouse cells, plated at concentra-
tions of 105 in 60 mm plastic petri dishes
(Greiner and Sohme, Niirtingen, Germany).
The cultures were made in duplicate using
Eagle's minimum essential medium supple-
mented with 10% foetal calf serum (Grand
Island Biological Company, Grand Island,
New York), and antibiotics. Foci were
counted on the 7th day.
RESULTS
Prevention of MSV-M tumour induction in
offspring of immunized mothers
The protective effects of immunized
mothers on tumour induction in their off-
spring were studied by challenging 1-2
week old micewith graded doses ofMSV-M
tumour extracts. These results are sum-
marized in Table I. It is evident that a
pronounced decrease in tumour incidence
occurred at the 3 dose levels in the animals
tested, compared with the controls. Tak-
ing the 3 dose levels together, 64 out of 143
(45%) born to MSV-M immunized mothers
developed tumours, while 330 out of 340
mice (97%) born to normal mothers
developed tumours. The mean latent
period for tumour induction was approxi-
mately the same in both groups and
appeared to depend upon the dilution of
the virus injected: 6, 8, and 15 days in
mice receiving 0-1, 0 01 and 0.001 gEq
respectively. Moreover, the incidence of
spontaneously regressing tumours was
remarkablyhigher inthe groups ofanimals
born to immune mothers.
TABLE I. Tumour Induction by MSV-M in BALB/c Mice Born to and Nursed by
Immunized Mothers
Nursing mother
Immunized
Normal
Immunized
Normal
Immunized
Normal
Tumour
extract
dilution
0-1
01
0-01
0-01
0.001
0-001
No. mice with
Total no. tumours
mice (%)
44 25 (57)*
70 70 (100)
71 30 (42)
245 239 (97 5)
28 9 (32)
25 21 (84)
No. mice with
regressed tumours
(%)
12 (48)t
0
22 (73)
5 (2)
5(55.5)
0
* Percentage of mice with tumours calculated from total number of mice.
t Percentage of mice with regressed tumours calculated from number of mice developing tumours.
I Percentage of mice dead with tumours calculated from number of mice developing tumours.
No. mice dead
with tumours
(0)
13 (52)t
70 (100)
7 (23)
231 (97)
4 (44)
21 (100)
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TABLE II.-Tumour Induction by MSV-M in BALB/c Mice Born to and Nursed by
Variously Treated Mothers'
No. mice with No. mice with No. mice dead
Total no. tumours regressing tumours with tumours
Nursing mother mice (%) (%) (%)
MSV-M exposed2 76 66 (87)* 4 (6)t 59 (89)t
Immunized po8t partum 23 23 (100) 0 23 (100)
Immunized before mating3 60 22 (37) 16 (73) 8 (36)
1 Offspring were injected with 0 05 ml of 0 01 gEq MSV-M tumour extract.
2 These mothers had previously nursed an MSV-M-injected litter.
3 Time interval between immunization and parturition varied from 9 to 32 weeks.
* Percentage of mice with tumours calculated from total number of mice.
t Percentage of mice with regressed tumours calculated from number of mice developing tumours.
I Percentage of mice dead with tumours calculated from number of mice developing tumours.
Data obtained when 1-2 week old mice
were nursed by variously treated mothers
and injected with 0-01 gEq tumour
extract are reported in Table II. A slight
reduction in tumour incidence was observ-
edin miceborntoMSV-Mexposedmothers
(87% compared with 97.5% in controls).
However, when tumour incidence was
analysed in each single litter, only 3 out of
14 litters showed a decrease in incidence
(Table III).
TABLE III.-Tumourigenesis in MSV-M
Injected BALB/c Mice Born to and
Nursed by MSV-M Exposed Mothers
Litter
size
3
>7
9
3
6
>4
9
5
3
5
8
>7
3
4
76
No. mice
with
tumours
3
4
9
3
6
1
9
5
3
5
8
1
2
4
66
(87%)
No. mice
with
regressed
tumours
0
3
0
0
0
0
0.
0
0
0
0
0
1
0
4
(16%)
No. mice
dead with
tumours
3
1
9
3
6
1
9
5
3
5
8
1
1
4
59
(89%)
> Litters with reduced tumour incidence.
Mice born to mothers immunized post
partum showed 100% tumours, in contrast
with mice born to mothers immunized long
before mating, which presented only 37%
tumours, the majority ofwhich eventually
regressed. In the latter animals no dif-
ferences were noted in tumour growth and
regression per single litter with regard to
the time interval between immunization
and parturition. Even 32 weeks after
immunization the mother could confer pro-
tection against MSV-M tumour develop-
ment in her offspring (Table IV).
In order to obtain direct evidence for
transfer of maternal immunity, the sera
from mothers and their litters were tested
for the presence of MSV-M neutralizing
antibodies by means of a focus reduction
method. From the results shown in
Table V, it is clear that sera from im-
munized mothers and their offspring con-
tained anti-MSV-M antibody (neutralizing
titresof8and4respectively). Incontrast,
sera from normal mothers and their litters
possessed no detectable neutralizing
activity.
Behaviour ofinduced tumours and rescue of
MSV-M oncogenic activity
Among the various experimental and
control groups described above, no signifi-
cant differences were observed in the
behaviour of MSV-M induced tumours.
The survival period of mice bearing pro-
gressive tumours was essentially the same,
and the mice usually died within 1-3
weeks. Some tumours developed more
than 2 months after MSV-M injection.
Moreover, in some of the mice whose
primary tumours hadregressed 2-7months
earlier there was a reappearance of
tumours, either at the injection site and/or
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TABLE IV.-Long-lasting Effect of Maternal Immunization on Tumour Induction by
MSV-M in BALB/c Mice
Time interval
between
immunization and
parturition
(weeks)
9
12
13
15
11
11
11
16
19
32
TABLE V.-MSV-M Neutralization Titres
of Sera from Immunized or Normal
Mothers and their Offspring
Serum donors
Immunized
mothers'
Offspring from
immunized
mothers2
Normal mothers
Offspring from
normal mothers2
Serum
dilution
2
4
8
16
2
4
8
16
2
4
8
16
2
4
8
16
Average
no. foci
5
3
18
29
10
19
25
35
36
36
39
38
37
38
38
38
1 BALB/c females received i.p. soon after mating
0-20 ml of gEq MSV-M, a second i.m. injection of
MSV-M, at the same dose, was given 10 days later.
Serum was collected and pooled 10 days after
parturition.
2 9 mice, 10 days old, served as donors of pooled
sera.
3Reciprocal of serum dilution that resulted in a
50% reduction of focus formation.
at different regions, i.e., chest muscles,
diaphragm and subcutaneous areas of the
abdomen. Histologically, the tumours
were essentially similar to those previously
reported (Chieco-Bianchi et al., 1971).
The late appearing or reappearing tumours
exhibited a marked lymphocytic infiltra-
tion within pleomorphic neoplastic cells,
reminiscent of the morphological pattern
of tumours undergoing regression.
Nine mice out of 642 inoculated with
MSV-M at 7-14 days of age developed leukaemia at 5-12 months of age. Cell-
free extracts were prepared from the
lymph nodes, spleen and thymus of 6 out
of these leukaemic mice. The extracts
were diluted to 0.1 gEq and 0 05 ml
injected i.m. into 1-week old mice.
Table VI reports the donor history as well
as the oncogenic activity ofthe leukaemic
extracts thus prepared. Typical MSV-M
tumours appeared 1-2 weeks afterinocula-
tion of4 out of6 ofthe extracts. Further-
more, extracts no. 2 and 5 gave rise to
leukaemia in the recipient animals.
DISCUSSION
Protection against leukaemia induc-
tion by Friend or Graffi virus has been
observed in mice born to and nursed by specifically immunized mothers (Mirand, Grace and Buffet, 1966; Mathot and
Scher, 1968; Chieco-Bianchi et al., 1970); similar protection against Gross virus in
rats has also been reported (Ioachim,
1970). The present study has revealed
that tumourigenesis byMSV-M inBALB/c mice can also beremarkably reduced ifthe
mother is specifically immunized. In
addition, the immune state of the mother
is enduring since MSV-M injected mice are
protected against tumour development
even when their mothers are immunized
several months before conception. Not
only did maternal immunity prevent
Litter no.
13704
13750
13783
13816
13825
13835
13866
13926
14025
14472
Litter size
4
3
8
5
8
9
3
6
8
6
60
No. mice with
tumours
0
3
2
4
8
3
1
0
1
0
22
No. mice with
regressed
tumours
0
3
2
3
4
2
0
0
0
0
16
No. mice
dead with
tumours
0
0
0
1
4
1
1
0
1 (late)
0
8
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TABLE VI.-Tumour Induction in Suckling Mice Injected with Extractfrom Mice
that Developed Leukaemia after MSV-M Inoculation
Donor history
t ..A
Mother
Immunized
Immunized
Immunized before mating
Normal
Normal
Normal
Dilution of
original MSV-M
extract
0-01
0*01
0-01
0*01
0-01
0.001
1 Number of mice with tumours/total number of mice.
* One mouse dead with leukaemia.
t Four mice dead with leukaemia.
Tumour
Regressed
Late appearing
No
No
No
No
Tumour induction
by cell-free
leukaemic
extract'
8/8
2/3*
0/4
9/11
0/5t
1/7
tumour induction but, perhaps more
significantly, it influenced the growth of
established tumours, as shown by the
occurrence of a good number of complete
regressions in the various experimental
groups. The protective phenomenon seen
in the offspring ofimmune mothers is best
explained by passive transfer (trans-
placental and/or by nursing) of humoral
antibodies possessing neutralizing activity
against MSV-M. Indeed, the results ob-
tained by the in vitro focus reduction assay
clearly demonstrate the presence of virus
neutralizing antibodies in the sera of mice
born to and nursed by immunized mothers.
In consideration of a previous report
(Bubenik et al., 1969) suggesting that
enhancement of tumour growth, rather
than suppression, may result following the
injection ofanti-MSV-M immune serum, it
is worthwhile to mention that such an
effect has not been noted in the present
experiments. It should be pointed out,
however, that enhancement of tumour
growth in the MSV-M and other tumour
systems has been observed for trans-
planted rather than for developing pri-
mary tumours (Harvey and East, 1971;
Kaliss, 1969).
Females immunized post partum did
not transfer any protection from MSV-M
tumourigenesis to their offspring. The
fact that not enough time elapsed to
develop an effective antibody titre after
immunization might explain this failure.
Also, it may be possible that protective
antibody transfer occurs exclusively
through the placenta during intrauterine
life. This last possibility seems most un-
likely, however, since passive transmission
of maternal immunity in the mouse takes
place mainly after birth through colostrum
and milk (Brambell, 1970). Moreover,
results of preliminary foster nursing
studies performed in our laboratory indi-
cate that mice born to normal mothers and
nursed by immunized females do in fact
show a lower incidence ofMSV-M induced
tumours (Chieco-Bianchi, unpublished
results).
A reduced number oftumours was also
observed in 3 out of 14 MSV-M-injected
litters whose mothers had been previously
exposed to the virus while nursing infected
offspring. A similar observation has been
madebyEssex etal. (1971), whofound that
kittens born to andnursed by mothers that
had previously nursed litters injected with
feline leukaemia virus were protected from
development of tumours following injec-
tion of feline sarcoma virus. These find-
ings suggest that horizontal transmission
of leukaemia and sarcoma viruses does
occur, albeit rarely, and that it may have
some practical significance under natural
conditions as well (Brodey et al., 1970).
A few MSV-M-injected mice did not
develop tumours but subsequently de-
veloped leukaemia. While activation of
" endogenous " virus cannot be com-
pletely ruled out, it is reasonable to
assume that these leukaemias were
Extract
no.
1
2
3
4
5
6
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induced bvMoloney leukaemia virus which
is usually present in high excess in MSV-M
tumour extracts. However, why leu-
kaemia should develop, even rarely, after
MSV-M tumour regression is not clearly
understood in view of the complete
immunological cross reactivity observed
between Moloney leukaemia and sarcoma
viruses (Hartley and Rowe, 1966; Chuat
et al., 1969). It is possible that the
immune system of the host is not opera-
tionally effective against leukaemia cells
due to their lesser immunosensitivity or a
' sneaking through " phenomenon. An-
other possibility is the fact that leukaemic
cell kinetics follow a logarithmic growth
curve which is unrelated to the viral sup-
ply. Development and growth ofMSV-M
tumours, on the other hand, seem to
depend upon a constantly high rate ofvirus
replication and continuous recruitment of
newly infected transformed cells.
This last hypothesis, supported by in
vitro (Bather, Leonard and Yang, 1968;
Parkman, Levy and Ting, 1970) and in
vivo findings (Chieco-Bianchi et al., 1971)
concurs with our present observation that
passive immunity is capable of effecting
tumour regression. Thus, when virus
synthesis is slowed down by a host reac-
tion or antibody transfer, prevention as
well as tumour regression may result.
The recovery of MSV-M oncogenic
activity from frankly leukaemic animals,
of which some had never presented
tumour, implies that MSV-M replicates at
low levels during the host's life span. This
is further substantiated by the late appear-
ance or recurrence of tumours in some of
the MSV-M inoculated mice. In fact,
Blumenschein and Moloney (1969) have
reported that virus is present in spleens
from MSV-M injected mice even 46 days
after inoculation, suggesting that the
spleen and possibly other reticuloendo-
thelial organs may be the carrier tissues for
continuing infection in the animal. These
considerations provide grounds for believ-
ing that when the host mechanisms con-
stantly operating to limit oncogenic
activity are undermined, then MSV-M
may reach titres high enough to induce
tumours.
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